CA3081423A1 - Antibacterial compounds - Google Patents
Antibacterial compounds Download PDFInfo
- Publication number
- CA3081423A1 CA3081423A1 CA3081423A CA3081423A CA3081423A1 CA 3081423 A1 CA3081423 A1 CA 3081423A1 CA 3081423 A CA3081423 A CA 3081423A CA 3081423 A CA3081423 A CA 3081423A CA 3081423 A1 CA3081423 A1 CA 3081423A1
- Authority
- CA
- Canada
- Prior art keywords
- 4alkyl
- group
- phenyl
- optionally substituted
- membered heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Warehouses Or Storage Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1718285.8 | 2017-11-03 | ||
| GBGB1718285.8A GB201718285D0 (en) | 2017-11-03 | 2017-11-03 | Antibacterial Compounds |
| PCT/GB2018/053183 WO2019086890A1 (en) | 2017-11-03 | 2018-11-02 | Antibacterial compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3081423A1 true CA3081423A1 (en) | 2019-05-09 |
Family
ID=60664899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3081423A Pending CA3081423A1 (en) | 2017-11-03 | 2018-11-02 | Antibacterial compounds |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11345694B2 (enExample) |
| EP (2) | EP3704105B9 (enExample) |
| JP (2) | JP7348897B2 (enExample) |
| KR (1) | KR102470319B1 (enExample) |
| CN (1) | CN111566099B (enExample) |
| AU (1) | AU2018361828B2 (enExample) |
| BR (1) | BR112020008531A2 (enExample) |
| CA (1) | CA3081423A1 (enExample) |
| CL (2) | CL2020001147A1 (enExample) |
| CO (1) | CO2020005420A2 (enExample) |
| EA (1) | EA202091118A1 (enExample) |
| ES (1) | ES3005164T3 (enExample) |
| GB (1) | GB201718285D0 (enExample) |
| GE (2) | GEP20237522B (enExample) |
| IL (1) | IL274229B2 (enExample) |
| MA (1) | MA50504A (enExample) |
| MX (2) | MX2020004562A (enExample) |
| PE (2) | PE20211390A1 (enExample) |
| SG (1) | SG11202003717UA (enExample) |
| UA (1) | UA128475C2 (enExample) |
| WO (1) | WO2019086890A1 (enExample) |
| ZA (1) | ZA202002093B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| MX2020010999A (es) | 2018-04-18 | 2021-01-20 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PE20220562A1 (es) | 2019-07-24 | 2022-04-13 | Constellation Pharmaceuticals Inc | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
| CN111635372B (zh) * | 2020-06-28 | 2022-05-27 | 齐鲁工业大学 | 一种恶唑酮衍生物及其合成方法 |
| IL308190A (en) | 2021-05-03 | 2024-01-01 | Discuva Ltd | Antibacterial compound |
| CN117597337A (zh) * | 2021-05-03 | 2024-02-23 | 迪斯库瓦有限公司 | 抗菌化合物的制备方法 |
| CN118647754A (zh) | 2022-02-21 | 2024-09-13 | 三井化学株式会社 | 金属构件、金属树脂接合体及金属构件的制造方法 |
| CN118164937A (zh) * | 2024-03-13 | 2024-06-11 | 北京联本医药化学技术有限公司 | 一种铵盐离子液体催化制备5-乙酰基-2,3-苯丙二氢呋喃的方法 |
| CN120208965B (zh) * | 2025-05-28 | 2025-08-12 | 四川大学 | 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物 |
| CN121471219A (zh) * | 2026-01-09 | 2026-02-06 | 四川大学 | 用于革兰氏阴性菌特异性抗菌治疗的咪唑-2-胺类衍生物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA869348B (en) | 1985-12-12 | 1987-10-28 | Smithkline Beckman Corp | Inhibition of the 5-lipoxygenase pathway |
| US4780470A (en) * | 1986-08-19 | 1988-10-25 | Smithkline Beckman Corporation | Inhibition of interleukin-1 by monocytes and/or macrophages |
| JP2808460B2 (ja) * | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
| JPH09124640A (ja) | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | ピリジルイミダゾール化合物、製法および農園芸用殺菌剤 |
| US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| EP1532118A2 (en) * | 2002-07-05 | 2005-05-25 | Axxima Pharmaceuticals Aktiengesellschaft | Imidazole compounds for the treatment of hepatitis c virus infections |
| JP2004196678A (ja) | 2002-12-17 | 2004-07-15 | Dainippon Pharmaceut Co Ltd | ピラゾール系誘導体 |
| AU2004289539C1 (en) | 2003-11-14 | 2012-06-07 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| NZ549003A (en) * | 2004-03-05 | 2009-07-31 | Taisho Pharmaceutical Co Ltd | Thiazole derivative as an ALK5 inhibitor |
| JP2007277230A (ja) * | 2006-03-15 | 2007-10-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| EP2513064B1 (en) | 2009-12-17 | 2018-07-04 | Katholieke Universiteit Leuven K.U. Leuven R&D | Compounds, compositions and methods for controlling biofilms |
| GB201016261D0 (en) | 2010-09-28 | 2010-11-10 | Univ Leuven Kath | Compounds for controlling biofilms and process for their production |
| WO2012135016A2 (en) | 2011-03-25 | 2012-10-04 | North Carolina State University | Inhibition of bacterial biofilms and microbial growth with imidazole derivatives |
| RU2612958C2 (ru) * | 2011-07-13 | 2017-03-14 | Ск Кемикалз Ко., Лтд. | 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4 |
| US8840912B2 (en) | 2012-01-09 | 2014-09-23 | North Carolina State University | Imidazole derivatives useful for controlling microbial growth |
| EP3142658B1 (en) * | 2014-05-16 | 2020-01-15 | Atriva Therapeutics GmbH | Novel anti-infective strategy against influenza virus and s. aureus coinfections |
| JP6836998B2 (ja) | 2015-03-02 | 2021-03-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ＴＧＦ−β阻害剤 |
| US20180044316A1 (en) | 2015-03-05 | 2018-02-15 | University Of Notre Dame Du Lac | Potentiators of beta-lactam antibiotics |
| WO2017011920A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
-
2017
- 2017-11-03 GB GBGB1718285.8A patent/GB201718285D0/en not_active Ceased
-
2018
- 2018-11-02 EP EP18800297.6A patent/EP3704105B9/en active Active
- 2018-11-02 PE PE2020000454A patent/PE20211390A1/es unknown
- 2018-11-02 CA CA3081423A patent/CA3081423A1/en active Pending
- 2018-11-02 JP JP2020524275A patent/JP7348897B2/ja active Active
- 2018-11-02 SG SG11202003717UA patent/SG11202003717UA/en unknown
- 2018-11-02 GE GEAP201815801A patent/GEP20237522B/en unknown
- 2018-11-02 BR BR112020008531-6A patent/BR112020008531A2/pt active IP Right Grant
- 2018-11-02 US US16/761,016 patent/US11345694B2/en active Active
- 2018-11-02 GE GEAP202315801A patent/GEAP202315801A/en unknown
- 2018-11-02 ES ES18800297T patent/ES3005164T3/es active Active
- 2018-11-02 MA MA050504A patent/MA50504A/fr unknown
- 2018-11-02 WO PCT/GB2018/053183 patent/WO2019086890A1/en not_active Ceased
- 2018-11-02 CN CN201880085171.5A patent/CN111566099B/zh active Active
- 2018-11-02 EA EA202091118A patent/EA202091118A1/ru unknown
- 2018-11-02 AU AU2018361828A patent/AU2018361828B2/en active Active
- 2018-11-02 MX MX2020004562A patent/MX2020004562A/es unknown
- 2018-11-02 UA UAA202003341A patent/UA128475C2/uk unknown
- 2018-11-02 PE PE2022000118A patent/PE20221006A1/es unknown
- 2018-11-02 EP EP24200101.4A patent/EP4606375A3/en active Pending
- 2018-11-02 KR KR1020207015574A patent/KR102470319B1/ko active Active
-
2020
- 2020-04-26 IL IL274229A patent/IL274229B2/en unknown
- 2020-04-30 CL CL2020001147A patent/CL2020001147A1/es unknown
- 2020-04-30 CO CONC2020/0005420A patent/CO2020005420A2/es unknown
- 2020-05-04 ZA ZA2020/02093A patent/ZA202002093B/en unknown
- 2020-07-13 MX MX2021010246A patent/MX2021010246A/es unknown
-
2021
- 2021-08-27 CL CL2021002263A patent/CL2021002263A1/es unknown
- 2021-11-01 JP JP2021178557A patent/JP2022025116A/ja not_active Withdrawn
-
2022
- 2022-04-25 US US17/728,335 patent/US20220372027A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018361828B2 (en) | Antibacterial compounds | |
| US11225477B2 (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
| CN103038229B (zh) | 杂芳基化合物及其使用方法 | |
| AU2012301953C1 (en) | Antibacterial compounds and methods for use | |
| AU2016287478A1 (en) | Antibacterial compounds | |
| CA3026010A1 (en) | Heterocyclic compounds as antibacterials | |
| WO2015058067A1 (en) | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors | |
| AU2014337154A1 (en) | Co-crystals of (s)-N-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as DNA-PK inhibitors | |
| CA3025727A1 (en) | Heterocyclic compounds as antibacterials | |
| AU2023342153A1 (en) | Brm targeting compounds and associated methods of use | |
| CA3151712A1 (en) | Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis | |
| EA041456B1 (ru) | Антибактериальные соединения | |
| WO2025221809A1 (en) | 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases | |
| AU2017218556A1 (en) | Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds | |
| WO2024123991A1 (en) | Treatment of autoimmune and inflammatory disorders with inhibitors of bet family bdii bromodomain | |
| TH87141A (th) | อนุพันธ์ควิโนลีนเป็นสารต้านแบคทีเรีย | |
| TH88486A (th) | อนุพันธ์ควินอลีนที่เป็นสารต้านแบคทีเรีย |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220927 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241024 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241024 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241024 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251020 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251020 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260414 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260717 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260721 |